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This paper summarizes the responses of panel-ists and audience to the issues surrounding
cardiovascular disease and lipoproteins presented
in the previous five papers by Rader, Castelli,
Brown, Stein, and Shepherd. Panelists were Virgil
Brown, Mark Hlarky, and William Castelli. San-
ford Schwartz moderated this session.
Moderator: We will start this session by asking
the panelists to share their reactions, thoughts,
and comments in the field of cardiovascular dis-
ease and lipoproteins.
Mark Hlatky: My research is in the area of out-
comes research and I found this presentation very
interesting. Different types of evidence were pre-
sented, including epidemiological evidence and ev-
idence from laboratory studies and clinical trials.
Outcomes research focuses on the bottom line,
that is, clinical benefit for the patient. So my ten-
dency is to focus on studies that provide a bottom
line answer. Many studies have been conducted in
this field with laboratory components, but the key
is that we are now seeing very large definitive
studies with endpoints measuring clinical benefit
meaningful to patients. With the right sort of out-
come data, a consensus is now emerging, and peo-
ple will start changing practices. From an eco-
nomic point of view, the most compelling evidence
comes from large, empirical studies measuring
outcomes and economic impact. Economic model-
ing is also useful but should be kept to a minimum
since real data will increase credibility and is the
most convincing.
Evan Stein: Jim [Shepherd] presented some inter-
esting hypotheses. The benefit of lipid-lowering
therapy was shown to be irrespective of absolute
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lowering of low density lipoprotein (LDL) choles-
terol. Hence, if noncompliers are excluded, any in-
dividual taking the drug should have equal bene-
fit. It would be interesting to examine those results
divided by quintiles, quartiles, or tertiles, Benefit
was also shown to be irrespective of the mecha-
nism involved to lower LOL cholesterol. With re-
spect to the issue on how far can we reduce 1.01.
cholesterol: Is more better? A few trials, such as
the Heart Protection Study (HBS2) currently being
done in Oxford and the LIPID trial [1], were de-
signed to provide some answers. In a study involv-
ing patients with familial hypercholesterolemia [2]
(2% of the US population), 1.01. cholesterol was
lowered from about 300 to 200 mg/dL, which was
the upper cholesterol level in the West of Scotland
Coronary Prevention Study Group (WOSCOPS)
[3]. Those patients benefited from this treatment in
terms of angiographic reversal. I think benefit is rel-
ative for each patient. Even though cholesterol level
might remain elevated for some treated individuals,
they still benefit from lipid-lowering therapy.
Bill Castelli: In the WOSCOPS study, LDL cho-
lesterol was reduced to 145 mg/dL on average,
and about 40% of patients had it reduced to 130
mg/dL. What would happen if the analysis was
performed differently, investigating the LOL level
at which there was a change in event rate?
Jim Shepherd: The same result was obtained
whether we examined absolute or relative reduc-
tion. If LOL cholesterol level was lowered by 20
mg/dL, which was the first quintile of reduction,
event reduction was minimal. If it was lowered by
35 mg/dL, the highest event reductions were ob-
tained. These reductions were not greater as LOL
cholesterol was lowered further in absolute terms.
Moderator: It might be interesting to see if this is
also the case in primary prevention versus second-
ary prevention. In the course of doing economic
analysis for the Scandinavian Simvastatin Survival
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Study Group (4S) [4], we observed that if individ-
uals with low LOL cholesterol levels had their lev-
els lowered further, they had fewer cardiovascular
events. We may have the opportunity to get some
insight into this issue with multiple trials and mul-
tiple therapies by performing the same type of
analyses as Jim [Shepherd] did for the WOSCOPS
study.
Jim Shepherd: This is an important issue because,
for ethical reasons, only individuals with LOL cho-
lesterol levels between 170 and 230 mg/dL were
enrolled in our trial, limiting the extent of our
findings. We need to investigate whether the same
kind of benefit can be obtained across a broad
spectrum of LDL cholesterol levels by conducting a
completely different trial or roll together other trials
such as the LIPID [11, CARE [5], and WOSCOPS
studies.
Bill Castelli: In a trial where LOL cholesterol lev-
els were not lowered to the goal of therapy for
most individuals, one can wonder what would
have happened with a more aggressive treatment.
Evan [Stein], you mentioned that high density lipo-
protein (HDL) cholesterol level was stable during
treatment, but LOL cholesterol was lowered and
the LDL/HDL ratio was modified. I believe this
ratio is the best predictor of what happened in all
those studies.
Euan Stein: The most effective way to lower the
LOLIHOL ratio is to lower LOL cholesterol level.
As Jim [Shepherd] mentioned, it is difficult to alter
one type of lipoprotein without altering the oth-
ers, because they are not discrete parameters; if
LOL receptors are increased, other elements are
also altered. In the Post-CABG study [61, in the
Lifestyle Heart Study [7], and in the STARS diet
study [81, HOL cholesterol was essentially the
same, whereas LOL cholesterol was lowered and
the ratio modified.
Bill Castelli: We know from the work of Con-
nors that HOL cholesterol increases in individuals
consuming cholesterol. This explains why levels in
America are much higher than in central China.
When cholesterol level is lowered, HOI. choles-
terol also goes down. However, LOL changes at a
rate four to five times greater than HOL, so when
you lower LOL with diet, you do lower HOL.
Still, the ratio does improve.
If we make an analogy with pneumonia and say
that a treatment is available to cure this disease in
30-40% of cases, we would not consider it a good
therapy. Why do we not obtain better results with
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lipid-lowering therapies. Probably other particles
are involved that we have not yet taken into con-
sideration.
Euan Stein: To treat pneumonia, the responsible
organism is first isolated and identified; otherwise
a broad-spectrum antibiotic must be used. Before
antibiotics were available, it was difficult to save
any individual affected with pneumonia; and if, at
that time, a treatment had been available to re-
duce the death rate by a third, it would have been
considered a good start. Today, some individuals
still die of pneumonia because of unidentified or
resistant micro-organisms. But there are a variety
of antibiotics now available to treat identified or-
ganisms. For coronary artery disease (CAO), we
have identified at least one agent involved, that is,
LOL cholesterol. For lipid-lowering therapy, there
is a need to conduct additional trials to investigate
the role of other factors.
Jim Shepherd: I would like to expand on the is-
sue of the dose used in our study. The WOSCOPS
trial was not aiming for a target lipid reduction, so
our study does not tell us what would have hap-
pened if we had prescribed 20 mg or 80 mg of
pravastatin rather than a fixed dose of 40 mg.
However, response to the treatment in our study
can be considered in two ways. Either individuals
with the best response to pravastatin were subjects
in whom its ancillary action on other issues such
as endothelial function and platelet adhesion was
more important; or, the drug was more effectively
switching on the LOL receptors of these individu-
als. In the second case, if an individual received
half of the treatment dose with the same reduction
in cholesterol, or in particle distribution, he would
achieve the same benefit in terms of event reduc-
tion since changes in the lipoprotein profile would
produce changes in event rates. Beyond measuring
LOL cholesterol, we need to measure changes in
triglyceride-rich particles. Investigating the ulti-
mate target(s) of this drug, which goes beyond
LDL cholesterol, is a crucial issue for understand-
ing drug dosage.
Virgil Brown: Jim [Shepherd], what about quin-
tile values? How many events occurred in the
treated group versus the placebo group in each
quintile, and how close was that to statistical sig-
nificance?
Jim Shepherd: The total number of events was
about 180 divided into quintiles. Half of those
events occurred in the first quintile; only a few in
the other quintiles.
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Virgil Brown: So, with a very small number of
events in those quintiles, results were more hy-
pothesis generating than providing answers.
Jim Shepherd: Absolutely. We need to conduct a
clinical trial to investigate the effect of drug dos-
ages on event reduction rates. For example, two
subgroups could be defined: one group would re-
ceive 10 mg of a lipid-lowering drug and the other
group would receive 80 mg of the same drug.
Virgil Brown: There is a definite need for dose-
ranging studies where one could examine whether
the hypothetical parameters identified in the
WOSCOPS study and other parameters can be
linked with the drug. WOSCOPS is an interesting
study that can help us focus on new questions per-
taining to those other 70% of events observed as
occurring in the treated group.
Concerning the time factor, the first 6 months
were not considered in WOSCOPS. Did you per-
form an analysis of the number of events that oc-
curred during the second half of the study, when
most of the benefit of the treatment could be ob-
served? Also, was there any confounding by the
fact that subjects in the first 6 months already had
some effective treatment?
Jim Shepherd: We excluded people in the first 6
months because we did not have information on
their lipid levels. Obviously, as the study went on,
the patients aged and the number of events per
treated patient increased. However, we did not
evaluate just the second half of the study in terms of
event reduction. That is something we could do.
Mark Hlatky: It would be interesting to hear
more about potential mechanisms and drug dos-
ages. In the old days, a number of interventions
were available but they were not very effective in
terms of clinical benefit. Powerful drugs are now
available which appear effective in reducing clini-
cal events. Can we generalize from a couple of
studies conducted with a specific drug and partic-
ular doses to all other statins? What about drugs
with different mechanisms?
Jim Shepherd: Statins are certainly different from
each other in their pharmacology, in their tissue
distribution, and presumably in their local effects.
Whether those differences translate to clinical
variations is unclear. A few trials should be per-
formed for each drug before we can answer that.
Moderator: There are a series of questions we
should address. What is the mechanism of action
of lipid-lowering drugs? To what extent is more
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better? What are the changes in cost effectiveness
of the intervention as cholesterol is increasingly
lowered.
Dan [Rader}: With respect to the mechanisms in-
volved, there is no clinical evidence that statins in
general have a direct effect on the vessel wall. Jim
(Shepherd) presented a post-hoc analysis suggest-
ing that possibility, but obviously other interpreta-
tions can be made. Is it biologically plausible, how
can one prove it, and is it important? Statins do
have effects on cells in culture in vitro. But con-
centrations needed are very high; can concentra-
tions achieved in vivo come close enough to those
in vitro to relate at least part of the benefit to LDL
reduction?
Jim Shepherd: Improvement in forearm blood-
flow or substance penetration into the myocar-
dium is observed when an individual receives a
statin. We do not know whether that is an effect
of the drug per se, or an effect of lowering choles-
terol and altering endothelial function. There may
be multiple benefits of starin therapy that go be-
yond LDL, but no data is available to evaluate ef-
fects independent of LDL reduction. Another diffi-
culty lies in extrapolating in vitro observations to
clinical practice. So far, differences among statins
are unresolved.
Evan Stein: The pleiotropic effects observed on
platelets and viscosity certainly may share a path-
way with cholesterol reduction in platelet mem-
branes. We know there is a relationship between
triglyceride lipoproteins and fibrogenic pathways.
We also know that the effect of statin on lipopro-
tein particles is more important in hypertriglyceri-
demic patients because more remnants in choles-
terol enriched VLDL and small VLDL are removed.
With respect to the difference between statins,
when cholesterol or lipoproteins in general are
lowered, a pleiotropic effect across a wide array of
parameters can be observed.
Bill Castelli: To address the question of how
soon the effects of a lipid-lowering therapy can be
observed in practice, I would like to mention that,
in our study [9], after a few months of treatment,
some patients had LDL cholesterol levels below
90-100 mg/dL, triglycerides below 90 mg/dL, and
they had lost their angina. Improvements in their
Doppler flow and other indicators were also ob-
served in a short period of time. Based on previous
clinical trial data, we told our patients that years
of treatment would be needed to see an improve-
ment in their condition, but that was not true. A
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study performed by Lance Gould [10] showed
that the positron emission tomography (PET) scan
of a patient could be normalized after 3 months
of cholesterol-lowering therapy. The therapy was
then stopped and the PET scan was abnormal
again two months later. In the Andrew's study, a
cholesterol-lowering treatment was prescribed for
6 months to 20 patients. Thirteen were cured, two
improved, one was stable, and one patient's con-
dition worsened.
Moderator: Virgil [Brown] showed in the CARE
study that 2 years of treatment were necessary to see
a statistically significant impact of the lipid-lowering
treatment on clinical events. In the WOSCOPS
study, the curve started separating at 6 months. Ob-
viously, clinical benefits can be observed earlier than
statistically significant differences.
Jim Shepherd: I agree with Bill [Castelli]. We
conducted a study with 10 patients for whom sur-
geons could do nothing and who were sent home,
essentially to die. Those individuals had a serious
problem but did not have a high cholesterol level
and nothing else was wrong with them. We gave
them a statin and other treatment for several months
and we observed all sorts of improvements in their
condition. We had to stop the treatment due to
funding and the patients died.
Moderator: The session is now open to questions
from the public.
Speaker 1: With respect to Jim Shepherd's presen-
tation, I agree with what has been said about sub-
group analyses, and I think it is possible that a
25'1"0 reduction in LDL might produce a maximum
benefit. But we do not know that yet. With respect
to the comparison of the Framingham-predicted
event rates and the actual pravastatin-treated event
rates, I would like to mention that predictions of
the Framingham model were pretty good [9].
However, it seems probable that predicted rates
matched up with observed rates because it was a
clinical trial rather than an observational study.
Jim Shepherd: I presented data with all the possi-
ble caveats, but you need to weigh the evidence
and decide for yourself. Although our placebo
group was not absolutely identical to the Framing-
ham males group, there was a difference between
the placebo group and the pravastatin-treated
group, independent of how absolute risk was cal-
culated.
Speaker 2: I think that using the simple concept
of an event is con fusing since all events are not
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equal. I would be surprised if changes in LDL cho-
lesterol levels had equal effect on the multitude of
scored events. The problem is, you would need a
huge database that cannot be obtained from a ran-
domized trial to investigate this. I am specifically
interested in the distinction between non-Q wave
heart attacks and Q wave heart attacks, which I
think are two different diseases. I believe that
early studies did not consider non-Q wave heart
attacks as heart attacks, and I wonder if results
would have been different if they had been taken
into consideration.
Bill Castelli: They were included as coronary in-
sufficiency, and reported throughout. Heart at-
tacks were part of total CHD, which, in the
Framingham study, included angina, coronary in-
sufficiency, myocardial infarction, sudden death
from CHD, and nonsudden death. Myocardial in-
farction did not include non-Q wave heart attacks
that were part of the coronary insufficiency syn-
drome.
Speaker 2: So, definitions and scoring have changed
and many more subendocardial infarcts are counted
today. In summary, each discrete outcome should
be studied rather than generalizing for cardiac
events. A huge dataset would then be needed, which
means that random control trials will not be suffi-
cient to obtain all the necessary information.
Jim Shepherd: I presented information only on
the primary endpoint to keep it simple. An eco-
nomic analysis of our data including the endpoints
you are interested in will be published shortly in the
British Medical Journal. It will provide far broader
insight into benefits of therapy in patients who are
making a transition from what we consider to be
perfect health to cardiovascular disease.
Mark Hlatky: The use of endpoints with multiple
pathophysiologies is an issue, particularly to ex-
pand the number of outcomes for smaller studies.
We should ensure that those outcomes have a
common underlying mechanism. For example, use
of coronary revascularization procedure is open to
a lot of subjective judgment and should not be
used as an endpoint. I think we need to focus on
clinical outcomes.
Virgil Brown: Given that, it is more impressive
when a very consistent change is observed in end-
points that have many other determinants.
Changes in cholesterol levels must be very power-
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ful to override all of these other variables and give
the same response for various endpoints, stroke,
for example.
Speaker 3: My primary concern is the clinical sig-
nificance of these different issues. Could you speak
about the significance of some of these other parti-
cles you mentioned earlier?
Jim Shepherd: Briefly, some lipoprotein particles
in the blood are more atherogenic than others.
The intermediate particle between VLOL (which is
the source of energy in the circulation in most in-
stances) and 1,01, (which is the waste product of
VLOL metabolism) is very atherogenic, as is the
remnant of the VLOL particle. We do have blood
samples from patients involved in the WOSCOPS
trial and I am planning to measure these different
particles to investigate whether these particles are
related to event reduction or risk.
Moderator: For the clinician, LOL cholesterol in-
cludes most of those particles. In addition, most of
the drugs that lower LOL also lower intermediate
density and remnant particles. Current guidelines
are sufficient since they incorporate these other
particles. It would also be very expensive and te-
dious to perform particle measurements on a regu-
lar basis.
Jim Shepherd: If we were to start over again, we
might not measure LOL as predictor for risk but
we might use a broader measure including LOL,
other particles, and VLOL remnants.
Bill Castelli: I think it is important to examine
other atherogenic particles, although their mea-
surement is difficult in practice. That is why we
also lower triglycerides for coronary patients to
reduce all those particles and have a better ratio.
To make an analogy with the treatment of hyper-
tension, reduction of blood pressure under 140
and 90 might not be sufficient since, even though
the absolute risk is not that high, half of heart at-
tacks and strokes in America occur in individuals
with a blood pressure between 120 and 140, and
80 and 90. That is why the Joint National Com-
mission on High Blood Pressure Control (.JNC VI)
recommendations [11] were set at 130 a few years
ago and might be modified shortly. We are taking
the same attitude with lipid-lowering therapies to
reduce blood lipids to very low levels.
Virgil Brown: I do not have any disagreement
with the idea that LOLIHOL ratio is a powerful
risk function and is superior to other measure-
ments. However, in the real world, we have not
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mastered HOL measurement yet. Plasma samples
may sit at 98QF from 1 to 72 hours before they get
to a laboratory, so I am not sure that measuring
remnant fractions is feasible yet.
Speaker 4: I agree with Virgil (Brown) for that
reason in particular but also because we incorpo-
rate HOL and a lot of other risk factors into our
risk assessment model. The ratio is a predictive
number, but, clinically, it is more realistic to in-
corporate HOL as a sole number along with other
risk factors, make an overall risk assessment, and
base the decision to treat on the overall risk assess-
ment rather than focusing disproportionately on a
ratio.
Bill Castelli: The only problem is that if you take
multiple risk and get a multiple risk score, you
need to define categories to make the decision to
treat. Treatments are different whether a patient
has hypertension, high blood sugar, or bad lipid
profile. For each one of those categories, goals
have to be set, therapy initiated, and carried out.
Speaker 5: Evan [Stein], why did you use univari-
ate analysis to perform the LOL cholesterol and
triglyceride analysis?
Evan Stein: The researchers of the 4S study per-
formed this analysis. They showed that there was
a univariate relationship between triglycerides and
LOL and HOL cholesterol levels, but that rela-
tionship disappeared when LOL cholesterol was
reduced.
Speaker 6: Bill [Castelli], you commented a lot
on the HOLILOL ratio and focused on the Fram-
ingham versus WOSCOPS analysis. Following Jim
Shepherd's comments on that analysis where they
controlled for HOL cholesterol and still observed
treatment effects, would you comment on the over-
lap analysis?
Bill Castelli: The issue is that if an individual's
risk is reduced, will he eventually have the same
event rate as another individual with the lower
number. According to Jim [Shepherd], a treated
individual will even have a lower event rate than
the untreated one with the low cholesterol level.
He might have had beneficial effects on endothe-
lial function and other mechanisms mentioned
earlier. It might even be that there was an effect on
some of these other parameters that were not con-
sidered in the Framingham formula.
Moderator: I think this is an important issue that
should be investigated further. If an individual
130
aged 55 years old with LDL cholesterol of 200
mg/dL receives a treatment to lower this level to
160 mg/dl., his body tolerance might be different
than that of a subject with the same age and LDL
cholesterol of 160 rng/dl, who received no treatment.
In fact, the treated person might be at lower risk
quantitatively although he appears to be at higher
risk. There is a lot to learn from those subgroups.
To close, we have learned a lot since our first
hypothesis about the benefits of lipid-lowering
therapy for CHD. Many questions have been an-
swered, but many more need response. We have
seen that individuals have reached a variety of
conclusions after examining data pertaining to
lipid-lowering therapy. Importantly, ongoing is-
sues are: (a) the emphasis we put on those conclu-
sions; (b) how we let them affect our clinical judg-
ment and treatments; and (c) whether we are
seeing drug class effects, LDL effects, or some-
thing else.
This paper is based on the discussionsof the Reactor Panel
(J. Sanford Schwartz, W. Virgil Brown, Mark Hlatky, and
William Castelli) at the TSPOR Lipid Conference and was
prepared with the assistance of BioMedCom Consultants
inc., Montreal, Canada.
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